6P Sensitization of pancreatic and colorectal cancer to radiotherapy, chemotherapy and inhibition of PD-1 expression by newly developed proprotein convertase inhibitors

Abstract

The pancreatic ductal adenocarcinoma (PDAC) and advanced colorectal cancer (CRC) have a bad prognosis with delayed diagnosis that significantly impedes the use of therapeutic resection. In these situation, palliative chemotherapy has modest activity, and Immune checkpoint inhibitors or radiotherapy failed to improve survival. The proprotein convertases (PCs) are enzymes involved in the biological activation/maturation of various protein precursors crucial for the malignant phenotype of PDAC and CRC tumors, and the resistance to various anticancer treatments.